BioRestorative Therapies, Inc..
BRTX.US | N/A
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. It develops programs relate to the treatment of disc/spine disease and metabolic disorders. The company's products pipeline comprises BRTX-100, a l...Show More
Better Health for All
0
No evidence available to assess BioRestorative Therapies, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
No evidence available to assess BioRestorative Therapies, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence available to assess BioRestorative Therapies, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific evidence was found in the provided article regarding BRTX.US's performance on fair trade certifications, supply chain audits, forced or child labor incidents, traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend.
1
The article discusses general industry standards and concerns, not company-specific data.
2
Honest & Fair Business
0
No relevant evidence was found in the provided article to assess BRTX.US against the 'Honest & Fair Business' ethical value.
1
The article indicated that data retrieval was throttled, preventing access to necessary information for all metrics.
2
Kind to Animals
-30
The company's research agreement with Pfizer, effective March 24, 2014,
1
stipulated compliance with Pfizer’s animal care and use policy,
2
which prohibits discretionary testing but allows legal mandates to override alternatives. In a specific study, 16 sheep were used for testing biorestorative polymeric coronary artery bypass grafts.
3
This study was conducted in accordance with the Guide for Care and Use of Laboratory Animals and ARRIVE guidelines, and was approved by the Test Facility’s Ethical Committee.
4
The company's lead cell therapy candidate, BRTX-100, is formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow,
5
and its ThermoStem platform also uses cell-based therapy candidates, indicating a focus on human-derived materials for its core products.
No War, No Weapons
0
No evidence available to assess BioRestorative Therapies, Inc. on No War, No Weapons.
Planet-Friendly Business
-20
BioRestorative Therapies, Inc. sources 48% of its total laboratory energy consumption from renewables.
1
In 2023, the company achieved a 22.7 metric tons reduction in CO2 emissions, a 44.2% decrease in water consumption, and a 37.5% reduction in laboratory waste.
2
Additionally, 82% of laboratory plastic consumables are recycled, and its research facilities hold LEED Gold certification.
3
The company invested $1.2 million in green technology upgrades in 2023 and optimized its cooling systems for a 29.4% energy reduction in the same year.
4
Respect for Cultures & Communities
0
No evidence was found in the provided articles regarding BioRestorative Therapies, Inc.'s performance or activities related to Respect for Cultures & Communities. The articles primarily consist of regulatory updates, SEC filings, or general company information that do not contain specific data points for any of the defined KPIs, such as formal partnerships with community groups, revenue reinvested in local development, cultural appropriation incidents, or cultural impact assessment protocols.
Safe & Smart Tech
0
No specific, concrete evidence was found in the provided article to assess the company against any of the 'Safe & Smart Tech' KPIs.
1
The article explicitly stated that data retrieval was throttled, resulting in no available information.
2
Zero Waste & Sustainable Products
-30
The company has implemented several waste and resource reduction initiatives. In 2023, it achieved a 37.5% reduction in laboratory waste.
1
It also recycles 82% of laboratory plastic consumables.
2
Additionally, the company has water conservation protocols that resulted in a 44.2% reduction.
3